Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is September 20, 2020.
All times in Eastern Daylight Time.
-
Janssen Presents Findings from Global, Multi-Centre Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
BEERSE, Belgium--(BUSINESS WIRE)--FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim res... more » -
LafargeHolcim Signs Net Zero Pledge with Science-Based Targets
ZUG, Switzerland--(BUSINESS WIRE)--Regulatory News: LafargeHolcim (Paris:LHN) LafargeHolcim joins the Science Based Targets initiative (SBTi) “Business Ambition for 1.5°C,” becoming the first globa... more » -
Limelight提供在线教育支持并赢得多个全球客户订单
亚利桑那州斯科茨代尔--(BUSINESS WIRE)--(美国商业资讯)--借助可满足维持全球教育机会空前需求的在线学习，内容交付网络(CDN)和边缘云服务的领先提供商Limelight Networks, Inc. (Nasdaq: LLNW)将帮助全球的教育科技(EdTech)公司向父母、学生及教师提供内容。 教育科技行业已几乎一夜之间发生改变。在短短的几个月内，远程学习已经从一项新兴... more » -
Limelight提供線上教育支援並贏得多筆全球客戶訂單
亞利桑那州斯科茨代爾--(BUSINESS WIRE)--(美國商業資訊)--憑藉可滿足維持全球教育機會空前需求的線上學習，內容傳遞網路(CDN)和邊緣雲端服務的領導廠商Limelight Networks, Inc. (Nasdaq: LLNW)將幫助全球的教育科技(EdTech)公司向父母、學生及教師提供內容。 教育科技業已幾乎一夜之間發生改變。在短短的幾個月內，遠距學習已經從一項新興的... more »
-
アンダーセン・グローバルがジャマイカでの協力を通じてカリブでのプレゼンスを拡大
サンフランシスコ--(BUSINESS WIRE)--（ビジネスワイヤ）-- アンダーセン・グローバルがジャマイカのシニア・アカウンティング・サービシズ・リミテッドとの協力契約を通じてカリブでのプレゼンスを拡大し、同地域での当組織の地理的な基盤を強化します。 マネジングディレクターのセリカ・スターリングにより2016年に設立された同事務所は、5名の専門家を擁し、個人、現地企業および多国籍企業... more »
-
ASIT biotech signe un préaccord de partenariat et sollicite une prorogation de son sursis de 2 moisBRUXELLES, Belgique--(BUSINESS WIRE)--Regulatory News : ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT - BE0974289218), société biopharmaceutique belge spécialisée dans la recherche et le développement... more »
-
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial
KENILWORTH, N.J.--(BUSINESS WIRE)--LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial more » -
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed ... more » -
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020 more » -
Hecla Reports Strong Production and Cash Generation
COEUR D'ALENE, Idaho--(BUSINESS WIRE)--Hecla Mining Company (NYSE:HL) reports strong production and cash generation in Q3 2020. more » -
Sotorasib (AMG 510) Shows Promising Results in Some Patients With Solid Tumors, Suggests a Study With City of Hope as a Co-Lead Author
DUARTE, Calif.--(BUSINESS WIRE)--A phase 1 clinical trial of AMG 510 in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity. more » -
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different ... more » -
リネージュ・ロジスティクス、事業成長の推進と技術・自動化への追加投資実現のため新規株式で16億ドルを調達
米ミシガン州ノバイ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 世界最大で最も革新的な温度管理産業用REIT・物流ソリューション提供企業のリネージュ・ロジスティクス（「リネージュ」または「当社」）は本日、新規・既存の戦略的パートナーから株式で16億ドルを調達したと発表しました。参加した投資家は、オックスフォード・プロパティーズ・グループ（オックスフォード・プロパティーズ）、... more » -
TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a clinically mea... more » -
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (ca... more »